AbbVie Inc.

Informe acción NYSE:ABBV

Capitalización de mercado: US$468.2b

AbbVie Crecimiento futuro

Future controles de criterios 4/6

Se prevé un crecimiento anual de los beneficios y los ingresos de AbbVie de 23.4% y 6.7% por año respectivamente. Se prevé que el BPA crezca en un 24.2% al año. Se espera que la rentabilidad financiera sea de 318.3% en 3 años.

Información clave

23.4%

Tasa de crecimiento de los beneficios

24.17%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs27.8%
Tasa de crecimiento de los ingresos6.7%
Rentabilidad financiera futura318.25%
Cobertura de analistas

Good

Última actualización20 Aug 2026

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Seeking Alpha • 2h

AbbVie Still Has Room To Run

Summary AbbVie continues to deliver robust top-line and EPS growth, with Skyrizi and Rinvoq strength offsetting Humira declines. Skyrizi and Rinvoq drive growth. Recent regulatory approvals and expanded market potential support AbbVie’s long-term positioning. Despite a forward P/E expansion to 18.89, AbbVie trades at a discount to the sector, with a non-GAAP forward PEG of 1.40 indicating undervaluation. I reiterate a buy rating on AbbVie, citing strong fundamentals, growth drivers, and opportunistic valuation despite pipeline and policy risks. Read the full article on Seeking Alpha
Actualización de narrativa • Aug 07

ABBV: Future Returns Will Hinge On Apogee Respiratory Bet

Analysts have nudged their fair value estimate for AbbVie higher to about $273 per share. This reflects refreshed models that factor in Q2 updates, stronger confidence in long term margins, and the potential impact of the Apogee acquisition, while still using a slightly higher discount rate and a modestly lower future P/E assumption.
Actualización de narrativa • Jul 24

ABBV: Future Returns Will Rely On Apogee Deal And Broader Pipeline Execution

AbbVie’s updated analyst price target has increased to $266.89 from $259.46 as analysts factor in recent Q2 preview research, higher modeled profit margins, and a slightly adjusted discount rate and future P/E outlook. Analyst Commentary Recent research commentary around AbbVie points to a broadly constructive tone ahead of Q2 results, with several firms revisiting their models, adjusting P/E assumptions, and updating margin and pipeline expectations.
Actualización de narrativa • Jul 10

ABBV: Future Returns Will Depend On Apogee Deal And Broader Immunology Expansion

AbbVie’s refreshed analyst price target framework edges higher to about $259 from roughly $254, with analysts pointing to updated Q2 models, recent target hikes across several firms, and added confidence around the Apogee acquisition’s immunology and respiratory potential as key supports for the revision. Analyst Commentary Recent research on AbbVie centers on two main themes, the refreshed Q2 earnings models and the planned Apogee Therapeutics acquisition.
Actualización de narrativa • Jun 23

ABBV: Future Returns Will Hinge On Apogee Deal And Immunology Pipeline

Analysts have made only a modest adjustment to AbbVie’s fair value narrative, reflecting a slightly higher discount rate and updated views on margins and long term P/E in light of the proposed $10.9 billion Apogee Therapeutics deal and its implications for competition and atopic dermatitis market potential. Analyst Commentary Recent research on AbbVie around the proposed US$10.9b Apogee Therapeutics acquisition highlights a mix of optimism about growth opportunities in immunology and atopic dermatitis, alongside caution about execution risk, competition, and valuation.
Artículo de análisis • Jun 16

AbbVie (ABBV) Stock Could Be 12.6% Undervalued After CLL14 Trial Update

AbbVie (ABBV) is back in focus after releasing nine year final results from its Phase 3 CLL14 trial, where a fixed duration venetoclax plus obinutuzumab regimen improved progression free survival in untreated CLL patients. See our latest analysis for AbbVie. The latest CLL14 update lands after a mixed few sessions for AbbVie, with the share price slipping 2.7% on the day to $221.59, while still showing a 5.3% 30 day share price return and a 19.9% one year total shareholder return that points...
Actualización de narrativa • Jun 06

ABBV: Future Returns Will Depend On Expanding Immunology And IBD Pipeline Execution

AbbVie’s updated analyst price target edges higher to $253.55 from $249.43 as analysts factor in slightly higher profit margin assumptions, modestly lower revenue growth expectations, a reduced discount rate, and a somewhat lower future P/E multiple, with recent research highlighting the depth of the inflammatory bowel disease pipeline and broader R&D optionality. Analyst Commentary Recent Street research on AbbVie shows a mix of optimism and caution, with multiple price target revisions clustered within a relatively tight range and commentary that keeps attention on the inflammatory bowel disease pipeline and broader R&D portfolio.
Artículo de análisis • May 15

We Think You Can Look Beyond AbbVie's (NYSE:ABBV) Lackluster Earnings

The market was pleased with the recent earnings report from AbbVie Inc. ( NYSE:ABBV ), despite the profit numbers being...
Actualización de narrativa • Apr 23

ABBV: Future Returns Will Rely On Immunology Expansion And Operating Leverage Execution

Analysts made a small upward adjustment to AbbVie’s fair value estimate to about $249. The modest change reflects a mix of slightly higher assumed discount rates and future P/E multiples, alongside recent shifts in Street price targets, including both raises and trims from firms such as Piper Sandler, Guggenheim, Cantor Fitzgerald, Evercore ISI, Citi and UBS, as well as fresh bullish initiations from Canaccord, RBC Capital and Barclays.
Actualización de narrativa • Apr 08

ABBV: Future Returns Will Hinge On Immunology Encore And Operating Leverage Execution

Analysts have made a modest upward adjustment to AbbVie’s price target, reflecting updated views on its immunology pipeline potential, operating leverage, and the ongoing debate about whether recent share underperformance and selloffs adequately reflect competitive risks. Analyst Commentary Recent research on AbbVie highlights a split view, with some analysts focusing on the upside from the immunology pipeline and operating leverage, while others point to valuation and competitive questions after a period of share underperformance.
Actualización de narrativa • Mar 24

ABBV: Future Returns Will Hinge On Immunology Encore Outweighing Competitive Concerns

Narrative Update The analyst price target for AbbVie has been adjusted slightly higher to reflect a fair value move to about $249. Analysts point to early stage indication expansion, operating leverage potential, and ongoing immunology pipeline developments, even as some firms flag emerging competition and a more balanced risk and reward profile.
Actualización de narrativa • Mar 10

ABBV: Future Returns Will Depend On Immunology Encore And Deal Optionality Uncertainty

The analyst price target for AbbVie edges higher to align with our fair value shift from $248.29 to $248.86, as analysts highlight ongoing indication expansion in immunology, potential operating leverage, and multiple expansion drivers, even as some firms note emerging competition and a more balanced risk and reward profile. Analyst Commentary Recent research on AbbVie reflects a split view, with some analysts pointing to upside tied to immunology growth and pipeline execution, while others flag competition risk and a more balanced risk and reward profile at current levels.
Actualización de narrativa • Feb 22

ABBV: Future Returns Will Rely On Immunology Encore And Evolving Deal Optionality

Our updated AbbVie narrative reflects a modest price target increase to about $248 per share, as analysts point to potential operating leverage, room for P/E multiple expansion, and a pipeline of proof-of-concept and immunology programs that could support slightly higher revenue growth assumptions, even as margin expectations are trimmed. Analyst Commentary Recent research shows a mix of optimism and caution around AbbVie, with several firms adjusting price targets and ratings as they reassess execution risks, competitive pressures, and the potential impact of the pipeline on valuation.
Actualización de narrativa • Feb 07

ABBV: Future Returns Will Depend On Immunology Pipeline Clarity And M&A Uncertainty

Analysts have trimmed their price targets for AbbVie by a small amount. This reflects slightly lower revenue growth and P/E assumptions, while also incorporating a modestly higher profit margin and recent mixed research views around competition and pipeline visibility.
Actualización de narrativa • Jan 24

ABBV: Future Returns Will Hinge On Post-Humira Immunology And Deal Optionality

Analysts have nudged their price target for AbbVie slightly higher to reflect a fair value estimate of about $245 per share, supported by updated assumptions for revenue growth, profit margins, and a modestly lower future P/E. Recent research highlights both increased price targets and more cautious views around competition and the sustainability of outperformance in key immunology drugs.
Actualización de narrativa • Jan 09

ABBV: Future Returns Will Depend On Post-Humira Immunology And Pipeline Execution

Analysts have trimmed their AbbVie fair value estimate by about $0.10 per share to roughly $244.56. This reflects a mix of slightly higher risk assumptions, modestly adjusted revenue and margin expectations, and a more balanced set of views after recent downgrades and price target changes that suggest outperformance is already well reflected in the current share price.
Artículo de análisis • Jan 08

AbbVie's (NYSE:ABBV) Dividend Will Be Increased To $1.73

AbbVie Inc. ( NYSE:ABBV ) will increase its dividend from last year's comparable payment on the 17th of February to...
Actualización de narrativa • Dec 21

ABBV: Future Returns Will Hinge On Post-Humira Immunology And Pipeline Execution

Analysts have nudged our AbbVie fair value estimate slightly higher, from $243.55 to $244.68. This reflects modestly stronger long term revenue growth expectations for key immunology franchises and pipeline assets, partially offset by slightly lower margin assumptions and a broadly constructive but mixed backdrop of recent price target revisions and rating changes across the Street.
Actualización de narrativa • Dec 07

ABBV: Future Performance Will Depend On Extended Exclusivity And Pipeline Execution

Analysts have nudged their average price target on AbbVie modestly higher to reflect a wave of target increases into the mid 240s to low 260s dollar range, supported by stronger visibility into Skyrizi and Rinvoq driven growth, extended Rinvoq exclusivity, and a more favorable large cap biopharma backdrop despite mixed ratings changes. Analyst Commentary Recent research paints a generally constructive picture on AbbVie, with most price target revisions skewing higher even as some firms move to the sidelines.
Artículo de análisis • Dec 02

AbbVie (NYSE:ABBV) Is Increasing Its Dividend To $1.73

The board of AbbVie Inc. ( NYSE:ABBV ) has announced that it will be paying its dividend of $1.73 on the 17th of...

Previsiones de crecimiento de beneficios e ingresos

NYSE:ABBV - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
FechaIngresosBeneficiosFlujo de caja libreFlujo de caja operativoNúm. de analistas medio
12/31/202879,06322,01036,58732,31918
12/31/202773,52018,91437,16030,44921
12/31/202667,58513,86224,78623,31822
6/30/202664,3866,27018,21019,507N/A
3/31/202662,8193,59719,98021,224N/A
12/31/202561,1604,18617,81619,030N/A
9/30/202559,6442,34819,68420,860N/A
6/30/202558,3283,72318,23919,283N/A
3/31/202557,3674,15515,38516,401N/A
12/31/202456,3344,23817,83218,806N/A
9/30/202455,5335,08115,62316,511N/A
6/30/202455,0005,29817,78018,638N/A
3/31/202454,4035,95121,89122,686N/A
12/31/202354,3184,82022,06222,839N/A
9/30/202355,1386,47124,72925,514N/A
6/30/202356,0238,63524,79925,542N/A
3/31/202356,7417,53523,52024,228N/A
12/31/202258,05411,78224,24824,943N/A
9/30/202257,81913,34321,92122,590N/A
6/30/202257,34912,56922,21422,923N/A
3/31/202256,72512,40722,04722,808N/A
12/31/202156,19711,46821,99022,777N/A
9/30/202155,1697,46521,67722,556N/A
6/30/202153,7296,59919,57220,451N/A
3/31/202150,1955,09217,78918,650N/A
12/31/202045,8044,55616,79017,588N/A
9/30/202040,6507,32415,32716,009N/A
6/30/202036,2276,90614,11514,734N/A
3/31/202034,0578,395N/A14,122N/A
12/31/201933,2667,842N/A13,324N/A
9/30/201932,8673,232N/A13,441N/A
6/30/201932,6244,093N/A13,410N/A
3/31/201932,6475,333N/A13,799N/A
12/31/201832,7535,657N/A13,427N/A
9/30/201832,1877,531N/A12,619N/A
6/30/201830,9466,419N/A11,366N/A
3/31/201829,6126,352N/A10,503N/A
12/31/201728,2165,283N/A9,960N/A
9/30/201727,2736,615N/A8,917N/A
6/30/201726,7106,582N/A7,100N/A
3/31/201726,2186,278N/A7,015N/A
12/31/201625,6385,923N/A7,041N/A
9/30/201625,2426,048N/A7,463N/A
6/30/201624,7545,690N/A8,164N/A
3/31/201623,7775,448N/A8,078N/A
12/31/201522,8595,118N/A7,535N/A
9/30/201521,9112,790N/A4,994N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (23.4% al año) de ABBV es superior a la tasa de ahorro (3.7%).

Beneficios vs. Mercado: Se prevé que los beneficios (23.4% al año) de ABBV crezcan más rápidamente que el mercado US (17% al año).

Beneficios de alto crecimiento: Se espera que los beneficios de ABBV crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (6.7% al año) de ABBV crezcan más despacio que el mercado de US (12.9% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 6.7% al año) de ABBV crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de ABBV sea muy elevada dentro de 3 años (318.3%).

Descubre empresas en crecimiento

7D

1Y

7D

1Y

7D

1Y

Análisis de la empresa y estado de los datos financieros

DatosÚltima actualización (huso horario UTC)
Análisis de la empresa2026/08/24 22:03
Precio de las acciones al final del día2026/08/24 00:00
Beneficios2026/06/30
Ingresos anuales2025/12/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

PaqueteDatosMarco temporalEjemplo Fuente EE.UU. *
Finanzas de la empresa10 años
  • Cuenta de resultados
  • Estado de tesorería
  • Balance
Estimaciones del consenso de analistas+3 años
  • Previsiones financieras
  • Objetivos de precios de los analistas
Precios de mercado30 años
  • Precios de las acciones
  • Dividendos, escisiones y acciones
Propiedad10 años
  • Accionistas principales
  • Información privilegiada
Gestión10 años
  • Equipo directivo
  • Consejo de Administración
Principales avances10 años
  • Anuncios de empresas

* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

AbbVie Inc. está cubierta por 51 analistas. 22 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

AnalistaInstitución
David ToungArgus Research Company
Emily FieldBarclays
Luisa HectorBerenberg